Orion Biotech Opportunities Corp. Units
ORIAU
ORIAU was delisted on the 25th of April, 2023.
0 hedge funds and large institutions have $0 invested in Orion Biotech Opportunities Corp. Units in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 4 closing their positions.
100% less funds holding
Funds holding: 4 → 0 (-4)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $15.6M → $0 (-$15.6M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP
JNE Partners
London,
United Kingdom
|
-$14.6M |
| 2 |
SIA
Schechter Investment Advisors
Birmingham,
Michigan
|
-$914K |
| 3 |
6CM
683 Capital Management
New York
|
-$9.76K |
| 4 |
CS
Clear Street
New York
|
-$8.3K |
ORIAU Hedge Fund Activity: Q2 2023 in Review
0 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Units (ORIAU) for Q2 2023, worth a combined $0 — down 100% from $15.6M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ORIAU and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was JNE Partners, exiting entirely with an estimated $14.6M sold.
- 0 institutional investors held Orion Biotech Opportunities Corp. Units (ORIAU) as of Q2 2023, down from 4 in Q1 2023.
- Funds reported $0 of Orion Biotech Opportunities Corp. Units stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Orion Biotech Opportunities Corp. Units positions in Q2 2023 and 4 closed out, a net change of -4 holders.
- The largest Orion Biotech Opportunities Corp. Units seller in Q2 2023 was JNE Partners, an estimated $14.6M sold.
Based on aggregated 13F filings for Q2 2023.